Business
Skin science patent grant
Skin science patent grant.
About this update from Hvivo Plc
[{"type":"text","content":"\n \nRNS Number : 9839J Venn Life Sciences Holdings PLC 19 June 2014 \n \n\n \n19 June 2014 \nVenn Life Sciences Holdings Plc\n(\"Venn\" or the \"Company\")\n \nVenn's first skin science patent grant ignites Innovenn's commercialisation stage\n \nVenn Life Sciences (AIM: VENN), a growing Clinical Research Organisation providing clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device clients, announces that its innovation division, Innovenn, has secured its first skin science patent for its unique anti-acne complex from the European Patent Office. The Company has also commenced commercial discussions on Labskin, the breakthrough research grade human skin testing platform.\n \nThis clinically proven Blemish Control Technology, developed by dermatologists over five years of scientific research, clinical and home usage trials, uniquely delivers a natural blend of actives deeper and faster into the epidermal skin layer than other commercially available treatments. The active complex reduces bacteria, inflammation, excess oiliness and blocked pores, resulting in noticeably clearer skin in less than four hours.\n \nThis breakthrough enables a compelling scientific platform for the commercial development of a new blemish management technology brand, expected to launch later this year. \n \nMeanwhile, commercial partnership discussions have commenced on Labskin following the establishment of new Innovenn laboratories and offices on the Innovation Campus at Sand Hutton, UK and the recruitment of a skin science management team. First revenue flows from Labskin are expected later this year.\n \nTony Richardson, CEO of Venn Life Sciences commented: \"After five years of dermatological research, testing and consumer trials, this patent grant confirmation from the European Patent office is a substantial step forward in the commercialisation of this unique anti-acne complex. Since our acquisition of the assets of Evocutis Plc. in March of 2014, Innovenn have made tremendous progress in terms of bringing our anti-acne and living skin equivalent technology to the marketplace.\" \n \nEnquiries:\n \n\n\n\n\nVenn Life Sciences Holdings Plc\n\n\nwww.vennlifesciences.com\n\n\n\n\nTony Richardson, Chief Executive Officer\n\n\nTel: +353 154 99 341\n\n...